Centene Corporation Raises Full-Year Earnings Guidance for Q2 2026
Centene Corporation raised its full-year adjusted EPS guidance to above $4.80 in Q2 2026, citing strong business performance and improved risk adjustment positioning across Marketplace segments. Medicaid results remained on track with disciplined execution of quality initiatives despite a slight increase in acuity due to population attrition. Medicare Advantage outperformed expectations, driven by favorable true-ups and lower-than-expected drug trends. The company is focusing on AI-driven data products for long-term differentiation while simplifying its Medicare footprint to better serve dual-eligible members using Medicaid expertise. Centene also expects breakeven or positive results in Medicare Advantage by 2027, despite challenges from the STARS program and industry-wide headwinds. Management highlighted a $180 million favorable risk adjustment development for Marketplace during Q2 but noted that one-time settlements will not recur in 2027. The company is also preparing for potential acuity impacts due to membership attrition, holding a reserve of 50 basis points.
Topics: ai_integration healthcare managed_care medicaid medicare